LONDON, Jan 4 (Reuters) - GW Pharmaceuticals Plc (GWP.L: Quote, Profile, Research) has won approval from U.S. regulators to conduct a pivotal Phase III study into its cannabis-based medicine Sativex as a treatment for cancer pain, the British drug company said on Wednesday.
